Zevra Therapeutics (NASDAQ:ZVRA) Stock Price Up 5.2% – Time to Buy?

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) was up 5.2% during trading on Friday . The stock traded as high as $9.36 and last traded at $9.5490. Approximately 230,059 shares changed hands during trading, a decline of 77% from the average daily volume of 992,670 shares. The stock had previously closed at $9.08.

Wall Street Analyst Weigh In

ZVRA has been the topic of a number of recent research reports. HC Wainwright set a $26.00 target price on Zevra Therapeutics in a research report on Tuesday, December 30th. Cantor Fitzgerald cut their price target on shares of Zevra Therapeutics from $29.00 to $24.00 and set an “overweight” rating for the company in a report on Thursday, November 6th. Wall Street Zen upgraded Zevra Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. Canaccord Genuity Group decreased their target price on shares of Zevra Therapeutics from $25.00 to $24.00 and set a “buy” rating on the stock in a research note on Thursday, November 6th. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of Zevra Therapeutics in a research report on Friday, January 9th. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $22.80.

Zevra Therapeutics Price Performance

The company has a market cap of $517.12 million, a PE ratio of 19.51 and a beta of 1.08. The company has a 50-day moving average price of $8.68 and a two-hundred day moving average price of $9.62. The company has a debt-to-equity ratio of 0.46, a current ratio of 8.62 and a quick ratio of 8.57.

Zevra Therapeutics (NASDAQ:ZVRA) last announced its earnings results on Wednesday, November 5th. The company reported ($0.01) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.03. Zevra Therapeutics had a negative return on equity of 51.40% and a net margin of 41.93%.The company had revenue of $26.06 million for the quarter, compared to analyst estimates of $26.64 million. Sell-side analysts expect that Zevra Therapeutics, Inc. will post -1.95 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Zevra Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of ZVRA. CWM LLC raised its position in Zevra Therapeutics by 399.5% in the third quarter. CWM LLC now owns 2,872 shares of the company’s stock worth $27,000 after acquiring an additional 2,297 shares in the last quarter. Ameritas Investment Partners Inc. grew its stake in Zevra Therapeutics by 30.0% in the second quarter. Ameritas Investment Partners Inc. now owns 5,541 shares of the company’s stock valued at $49,000 after purchasing an additional 1,280 shares in the last quarter. Russell Investments Group Ltd. raised its position in Zevra Therapeutics by 235.7% during the third quarter. Russell Investments Group Ltd. now owns 6,374 shares of the company’s stock valued at $61,000 after acquiring an additional 4,475 shares in the last quarter. Tower Research Capital LLC TRC lifted its stake in shares of Zevra Therapeutics by 617.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 9,937 shares of the company’s stock valued at $88,000 after purchasing an additional 8,552 shares during the last quarter. Finally, Creative Planning acquired a new position in Zevra Therapeutics during the second quarter valued at approximately $92,000. 35.03% of the stock is currently owned by institutional investors.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.